Suspected silent pituitary somatotroph neuroendocrine tumor associated with acromegaly-like bone disorders: a case report
BMC Endocrine Disorders · 2024
DOI: 10.1186/s12902-024-01657-7 ↗Kurz gefasst
Fallbericht in der Zeitschrift BMC Endocrine Disorders, 2024. Verfasst von Tongxin Xiao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases …. Hauptthemen laut MEDLINE: Acromegaly, Neuroendocrine Tumors, Pituitary Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Growth hormone (GH) positive pituitary neuroendocrine tumors do not always cause acromegaly. Approximately one-third of GH-positive pituitary tumors are classified as non-functioning pituitary tumors in clinical practice. They typically have GH and serum insulin-like growth factor 1 (IGF-1) levels in the reference range and no acromegaly-like symptoms. However, normal hormone levels might not exclude the underlying hypersecretion of GH. This is a rare and paradoxical case of pituitary tumor causing acromegaly-associated symptoms despite normal GH and IGF-1 levels. Case presentation We report a case of a 35-year-old woman with suspicious acromegaly-associated presentations, including facial changes, headache, oligomenorrhea, and new-onset diabetes mellitus and dyslipidemia. Imaging found a 19 × 12 × 8 mm pituitary tumor, but her serum IGF-1 was within the reference, and nadir GH was 0.7ng/ml after glucose load at diagnosis. A thickened skull base, increased uptake in cranial bones in bone scan, and elevated bone turnover markers indicated abnormal bone metabolism. We considered the pituitary tumor, possibly a rare subtype in subtle or clinically silent GH pituitary tumor, likely contributed to her discomforts. After the transsphenoidal surgery, the IGF-1 and nadir GH decreased immediately. A GH and prolactin-positive pituitary neuroendocrine tumor was confirmed in the histopathologic study. No tumor remnant was observed three months after the operation, and her discomforts, glucose, and bone metabolism were partially relieved.
Conclusions
GH-positive pituitary neuroendocrine tumors with hormonal tests that do not meet the diagnostic criteria for acromegaly may also cause GH hypersecretion presentations. Patients with pituitary tumors and suspicious acromegaly symptoms may require more proactive treatment than non-functioning tumors of similar size and invasiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Scie…
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zitieren
APA
Xiao, T., Mao, X., Wang, O., Yao, Y., Deng, K., Zhu, H., & Duan, L. (2024). Suspected silent pituitary somatotroph neuroendocrine tumor associated with acromegaly-like bone disorders: a case report. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-024-01657-7
Vancouver
Xiao T, Mao X, Wang O, Yao Y, Deng K, Zhu H, et al. Suspected silent pituitary somatotroph neuroendocrine tumor associated with acromegaly-like bone disorders: a case report. BMC Endocrine Disorders. 2024. doi:10.1186/s12902-024-01657-7
BibTeX
@article{Xiao2024,
author = {Xiao, Tongxin and Mao, Xinxin and Wang, Ou and Yao, Yong and Deng, Kan and Zhu, Huijuan and Duan, Lian},
title = {Suspected silent pituitary somatotroph neuroendocrine tumor associated with acromegaly-like bone disorders: a case report},
journal = {BMC Endocrine Disorders},
year = {2024},
doi = {10.1186/s12902-024-01657-7}
}
EUVIMED